Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.03.7960 on January 3 2006

Journal of Clinical Oncology, Vol 24, No 5 (February 10), 2006: pp. 798-804
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, H.
Right arrow Articles by von der Maase, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, H.
Right arrow Articles by von der Maase, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Serum YKL-40 Predicts Relapse-Free and Overall Survival in Patients With American Joint Committee on Cancer Stage I and II Melanoma

Henrik Schmidt, Julia S. Johansen, Pia Sjoegren, Ib J. Christensen, Boe S. Sorensen, Kirsten Fode, Jorn Larsen, Hans von der Maase

From the Departments of Oncology, Plastic Surgery, and Clinical Biochemistry, Aarhus University Hospital; Department of Rheumatology, Herlev University Hospital, Herlev; and the Department of Surgical Gastroenterology, Hvidovre University Hospital, Hvidovre, Denmark

Address reprint requests to Henrik Schmidt, MD, Department of Oncology, Aarhus University Hospital, Norrebrogade 44, 8000 Aarhus C, Denmark; e-mail: hesch{at}as.aaa.dk

PURPOSE: To evaluate the novel tumor biomarker YKL-40 in serial serum samples from patients with American Joint Committee on Cancer (AJCC) stage I and II melanoma from the time of diagnosis and during routine follow-up. Macrophages, neutrophils, and cancer cells secrete YKL-40, and a high serum level has been associated with poor prognosis in patients with several cancer types.

PATIENTS AND METHODS: Serum samples from 234 patients with stage I (n = 162) and II (n = 72) melanoma were analyzed for YKL-40 by enzyme-linked immunosorbent assay. Serial samples were obtained before definitive primary surgery and during follow-up.

RESULTS: After a median follow-up period of 66 months (range, 1 to 97 months), 41 relapses (18%) and 39 deaths (17%) were observed. Serum YKL-40 treated as an updated continuous covariate were analyzed together with the covariates sex, age, primary tumor site, ulceration, thickness, Clark level and histologic subtype in a Cox proportional hazard model. Serum YKL-40 was an independent prognostic factor of relapse-free survival (hazard ratio [HR], 1.6; 95% CI, 1.1 to 2.5; P = .03) and overall survival (HR, 1.8; 95% CI, 1.2 to 2.6; P = .002) together with thickness and ulceration. The serum level of YKL-40 (dichotomized as normal or elevated) at the time of diagnosis was also an independent prognostic factor for overall survival (HR, 3.6, 95% CI, 1.7 to 7.7; P = .001).

CONCLUSION: Serum YKL-40 may be an early biomarker of relapse and survival in patients with AJCC stage I and II melanoma. Serum YKL-40 may also be useful for patient stratification and follow-up in clinical trials. Our results need confirmation in an independent study.

Supported by grants awarded by the Danish Cancer Society, "Direktor Jens Aage Sorensen og Hustru Edith Ingeborg Sorensens Mindefond," "Aase og Ejner Danielsens Fond," and "Radiumstationens forskningsfond."

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
H. Gogas, A. M. M. Eggermont, A. Hauschild, P. Hersey, P. Mohr, D. Schadendorf, A. Spatz, and R. Dummer
Biomarkers in melanoma
Ann. Onc., August 1, 2009; 20(suppl_6): vi8 - vi13.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. S. Johansen, S. E. Bojesen, A. K. Mylin, R. Frikke-Schmidt, P. A. Price, and B. G. Nordestgaard
Elevated Plasma YKL-40 Predicts Increased Risk of Gastrointestinal Cancer and Decreased Survival After Any Cancer Diagnosis in the General Population
J. Clin. Oncol., February 1, 2009; 27(4): 572 - 578.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. Mitsuhashi, H. Matsui, H. Usui, Y. Nagai, S. Tate, Y. Unno, K. Hirashiki, K. Seki, and M. Shozu
Serum YKL-40 as a marker for cervical adenocarcinoma
Ann. Onc., January 1, 2009; 20(1): 71 - 77.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. S. Johansen, T. Lottenburger, H. J. Nielsen, J. E. B. Jensen, M. N. Svendsen, G. Kollerup, and I. J. Christensen
Diurnal, Weekly, and Long-Time Variation in Serum Concentrations of YKL-40 in Healthy Subjects
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2603 - 2608.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. S. Johansen, K. Brasso, P. Iversen, B. Teisner, P. Garnero, P. A. Price, and I. J. Christensen
Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival
Clin. Cancer Res., June 1, 2007; 13(11): 3244 - 3249.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. Schmidt, S. Suciu, C. J.A. Punt, M. Gore, W. Kruit, P. Patel, D. Lienard, H. von der Maase, A. M.M. Eggermont, and U. Keilholz
Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy Trial
J. Clin. Oncol., April 20, 2007; 25(12): 1562 - 1569.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online